To break it down: The first part, HER2, stands for “human epidermal growth factor receptor 2”. This refers to a protein found on the surface of breast cells that helps direct how quickly those ...

Both rare and aggressive, triple-negative breast cancer accounts for 10-15% of all breast cancers. Dr. Bhardwaj says, “TNBC ...

Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

2008;5(9):531-542. Thus, in HR + /HER2 + breast tumors a vicious cycle is established between ER genomic and non-genomic mechanisms of action and the growth factor receptor network leading to ...